Searchable abstracts of presentations at key conferences in endocrinology

ea0074ncc33 | Highlighted Cases | SFENCC2021

Pituitary apoplexy in the setting of recent COVID-19 infection

Seese Rachel , Shames Abdul , Liew Su-Yi

Section 1: Case history: We present a case of a 75-year-old male with hypopituitarism on the background of recent COVID-19 infection. The patient was COVID-19 swab positive six weeks prior and suffered mild hypoxia, however declined hospital admission at that time. He presented one month later with sudden onset severe headache associated with fever; drowsiness and abdominal pain. He was discharged with antibiotics for suspected diverticulitis. His GP subsequently performed a p...

ea0041ep657 | Female Reproduction | ECE2016

Immunity to Haemophilus influenzae B and Peumococcal vaccination among adult women with Turner Syndrome

Bukowczan Jakub , Liew Aaron , Roberts Graham , Spickett Gavin , Quinton Richard

Introduction: Turner Syndrome (TS) is associated with a higher overall morbidity and mortality than the general population, with respiratory diseases as one of the major causes. Haemophilus influenza type B (HiB) and pneumococcal (PC) vaccination can reduce morbidity and mortality, by alleviating the risk of respiratory diseases. All patients in the Newcastle Adult Turner Syndrome clinic who lack immunity to either HiB or PC at baseline receive vaccination in our TS clinic. Ho...

ea0073aep33 | Adrenal and Cardiovascular Endocrinology | ECE2021

Initial therapy with empagliflozin in addition to metformin vs standard therapy alone for patients with type 2 diabetes mellitus and cardiovascular disease in qatar. A cost-effectiveness analysis

Abushanab Dina , Al-Badriyeh Daoud , Liew Danny , Ademi Zanfina

BackgroundSodium-glucose cotransporter 2 (SGLT2) inhibitors have been shown to reduce deaths and cardiovascular events in patients with type 2 diabetes mellitus (T2DM), but are currently not used as first-line therapy.ObjectiveTo evaluate the cost-effectiveness of introducing empagliflozin into the current standard care (metformin monotherapy) for patients with newly diagnosed T2DM and existing cardiovascular...

ea0044p57 | Bone and Calcium | SFEBES2016

Initial experience of a newly established intra-operative PTH service

Lekkakou Leoni , Kandaswamy Leelavathy , Rolli Alain , Ford Claire , Garnham Andrew , Spinou Catherine , Liew Lenny , Buch Harit

Background: A minimally invasive approach to primary hyperparathyroidism (PHPT) is equivalent to bilateral exploration when intraoperative parathyroid hormone (iPTH) monitoring is used. We have recently established an iPTH service jointly with Surgical and Clinical Chemistry teams and the aim of the study was to evaluate our initial results with its use.Patients and methods: We collected data from 18 operations for PHPT from October 2015, including one r...

ea0037ep1155 | Clinical Cases–Pituitary/Adrenal | ECE2015

Case report: adrenal phaeochromocytoma presenting with ileus, renal vein thrombosis and pulmonary embolism

Lai Ray , Lee Daphne , Liew Huiling , Quek Timothy Peng Lim , Seow Cherng Jye

Introduction: We report a patient who presented with presumed intestinal obstruction, and was subsequently diagnosed with an adrenal phaeochromocytoma associated with venous thromboembolism. We review the literature and discuss underlying mechanisms for these uncommon manifestations.Case presentation: A 56-year-old man with background untreated hypertension presented with abdominal distension, vomiting, breathlessness and haemoptysis. Heart rate (HR) was...

ea0007p145 | Neuroendocrinology and behaviour | BES2004

The insulin tolerance test (ITT) in clinical practice: the experience of a busy pituitary unit

Liew A , Agha A , Finucane F , Thornton E , Rogers B , Tormey W , Thompson C

The insulin tolerance test (ITT) is the gold standard for assessing growth hormone (GH) and cortisol production in pituitary disease, However it is potentially hazardous, requires medical supervision and adequate hypoglycemia may not be achieved. We retrospectively examined the records of 185 consecutive patients aged 14-76 years with pituitary disease who underwent the ITT over 18 months. Testing was performed in the endocrine day ward by an experienced endocrine nurse. Absol...

ea0007p198 | Steroids | BES2004

Conventional corticosteroid replacement therapy may overtreat adult hypopituitary patients with partial ACTH deficiency

Agha A , Liew A , Finucane F , Baker L , O'Kelly P , Tormey W , Thompson C

Corticosteroid therapy is associated with potentially serious side effects, but there is no information available regarding glucocorticoid requirements in adult hypopituitary patients with partial adreno-corticotrophin hormone (ACTH) deficiency.10 male adult hypopituitary patients with partial ACTH deficiency, baseline plasma cortisol > 200 nanomole/ litre but a peak stimulated cortisol < 550 nanomole/ litre, were randomised to a cross-over protoco...

ea0073aep17 | Adrenal and Cardiovascular Endocrinology | ECE2021

Cost-effectiveness of empagliflozin plus metformin vs metformin alone as first-line therapy in patients with type 2 diabetes mellitus: An australian perspective

Abushanab Dina , Liew Danny , marquina Clara , Al-Badriyeh Daoud , Ademi Zanfina

BackgroundSodium-glucose cotransporter 2 (SGLT2) inhibitors are potentially an attractive option for initial combination therapy with metformin for type 2 diabetes mellitus (T2DM), which may help patients to achieve adequate glycaemic control and reduce cardiovascular disease (CVD). Empagliflozin has been shown to be superior compared to other SGLT2 inhibitors in reducing all-cause and cardiovascular mortality in patients with T2DM.<p class="abstext"...

ea0041ep500 | Diabetes complications | ECE2016

Audit of management of cystic fibrosis related diabetes mellitus in Nottingham University Hospital

Yahia Seifeldin , Liew Kok Kee , Mahendra Pramya , Paszkiewicz Adrian , HLA Tun Win , Kalk William , Clayton Andy , Dewar Jane

Introduction: Patients with Cystic fibrosis are now living longer due to advances in nutritional and medical care. As a consequence a larger number are developing related co-morbidities such as cystic fibrosis related diabetes (CFRD). CFRD is the most common co-morbidity in CF, with the prevalence being up to 50% by the age of 30.Aims: To assess current practice in relation to the UK CF Trust guidelines 2004 – Screening for CFRD should begin at age ...

ea0092op-06-01 | Oral Session 6: Pregnancy | ETA2023

Antithyroid drug exposure during 1,191,904 pregnancies in denmark: a 20-year longitudinal study before and after implementation of iodine fortification

Maria Uldall Torp Nanna , Liew Zeyan , Carle Allan , Scott Karmisholt Jesper , Bulow Pedersen Inge , Andersen Stig , Linding Andersen Stine

Objectives: Hyperthyroidism in pregnant women is a clinical concern, and it is important to surveil any change in the occurrence of hyperthyroidism within the pregnant population specifically, especially when a mandatory iodine fortification (IF) program is implemented as it was in Denmark in the year 2000. This longitudinal study aimed to investigate any change in the use of antithyroid drugs (ATD) for the treatment of hyperthyroidism in Danish pregnant women during a 20-year...